In light of these findings, we asked whether elevated CEBPA level and not the CEBPA mutation(s) per se, drives the selective pressure for GATA2 and/or TET2 loss in AML to achieve moderate GATA2 levels that are optimal for leukemia growth. The gene discussed is GATA2; the disease is leukemia.